AI Article Synopsis
- Researchers explored the effects of adding cisplatin and etoposide (EoP) to standard chemotherapy in early breast cancer patients with 4 or more positive lymph nodes.
- 41 patients received a combination of EoP followed by standard treatments, while a control group was given only the standard regimen (AC + T).
- Although no long-term side effects were found with EoP, survival rates between the two groups were similar, prompting the need for further randomized trials to investigate potential benefits of the additional treatment.
Article Abstract
Background And Objectives: Previous reports suggest that including cisplatin plus etoposide in the adjuvant treatment may improve the outcomes in patients with early breast cancer.
Patients And Methods: Forty-one patients with early breast cancer and 4 or more positive lymph nodes were treated with 3 cycles of EoP (oral etoposide plus cisplatin) in addition to 3 cycles of AC (doxorubicin plus cyclophosphamide) and 3 cycles of T (docetaxel) (Group 1). Toxicity and survival results were compared to those with similar disease characteristics who were treated with 4 cycles of AC plus 4 cycles of T (Group 2) during the same period.
Results: There were no long-term side effects related to EoP. While median disease-free and overall survivals were not reached in Group 1, they were 107 ± 13 (p = 0.387) months and 123 ± 5 months (p = 0.618) in Group 2. Likewise 10-year disease-free survivals (DFS) were 59.3% and 44.7% respectively.
Conclusions: The trend towards improvement in survival with adjuvant AC + T + EoP when compared to AC + T needs to be studied in randomized trial.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.breast.2010.09.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transforming cancer screening: the potential of multi-cancer early detection (MCED) technologies.
Int J Clin Oncol
January 2025
Translational Research Support Section, National Cancer Center Hospital East, Chiba, Japan.
Early cancer detection substantially improves the rate of patient survival; however, conventional screening methods are directed at single anatomical sites and focus primarily on a limited number of cancers, such as gastric, colorectal, lung, breast, and cervical cancer. Additionally, several cancers are inadequately screened, hindering early detection of 45.5% cases.
View Article and Find Full Text PDFAssociations of early life body size and pubertal timing with breast density and postmenopausal breast cancer risk: a mediation analysis.
Ann Epidemiol
January 2025
Center for Clinical Research and Prevention, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark.
Purpose: Whether breast density mediates associations between early life body size and pubertal timing with postmenopausal breast cancer is underexplored.
Methods: We studied 33,939 Danish women attending the Capital Mammography Screening Program at ages 50-69 years. Early life anthropometry and pubertal timing information came from the Copenhagen School Health Records Register.
Enhance registration precision of transmission breast images utilizing improved Levenberg-Marquardt optimization algorithm with normalized cross-correlation.
Comput Biol Med
January 2025
State Key Laboratory of Precision Measuring Technology and Instruments, Tianjin University, Tianjin, 300072, China. Electronic address:
Transmission imaging may become a possible advance for breast cancer screening with non-invasive, cost-effective, and radiation-free approaches for early detection. Frame accumulation can successfully eliminate the issue of low SNR, low grayscale and poor quality in transmission image. However, frame accumulation accuracy can be diminished because of inherent human body instability during image acquisition and the light absorption characteristics of breast tissue, resulting in distorted and misplaced image sequences.
View Article and Find Full Text PDFA multicenter retrospective study of early cardiac toxicity in operable breast cancer patients receiving concurrent dual or mono anti-HER2 therapy with postoperative radiation therapy.
Breast
January 2025
Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200025, China; Shanghai Key Laboratory of Proton Therapy, Shanghai, 201801, China. Electronic address:
Purpose: This study aims to assess whether dual anti-HER2 therapy with trastuzumab and pertuzumab increases early cardiac toxicity compared to trastuzumab alone in breast cancer (BC) patients receiving postoperative radiation therapy (RT).
Methods: Consecutive operable BC patients receiving postoperative RT and trastuzumab with or without pertuzumab between January 2017 and September 2020 at seven tertiary hospitals in China were retrospectively reviewed. Cardiac examinations included echocardiography, electrocardiogram (ECG), NT-proBNP, and cTnI at baseline before RT and during the follow-up.
Predictive Value of Dynamic Contrast-Enhanced Breast Magnetic Resonance Imaging and Diffusion-Weighted Imaging Findings for Sentinel Lymph Node Metastasis in Early-Stage Invasive Breast Cancer.
Br J Radiol
January 2025
Department of Radiology, Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, TURKEY.
Objective: This retrospective study aimed to evaluate the predictive value of the preoperative dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and diffusion-weighted imaging (DWI) findings of mass lesions for predicting sentinel lymph node (SLN) metastasis in early breast cancer.
Methods: A total of 310 patients with suspicious mass lesions detected in preoperative MRI who subsequently underwent surgery and SLN biopsy (SLNB) between September 2015 and September 2022 were analyzed. The relationship between DCE-MRI and DWI findings and SLNB positivity was analyzed.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!